Heartflow 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Heartflow Inc. reported 3rd quarter 2026 revenue of $72.9 million, up 57.4% year over year; U.S. revenue was $67.9 million, up 60%, and OUS and other revenue was $4.9 million.
- Global revenue cases reached 98,155, up 89.5% year over year, and U.S. revenue growth was the fastest in 11 quarters.
- Plaque revenue was $11.8 million in the quarter, with adoption and utilization expanding across new and existing accounts.
- 3rd quarter gross margin was 83.8%, compared with 76.8% in the 3rd quarter of 2025, reflecting volume leverage, increased plaque revenue, and AI-driven production efficiency.
- Non-GAAP operating expenses were $66.1 million, or 90.7% of revenue, compared with 100.9% a year ago; non-GAAP operating loss narrowed to $5 million from $11.1 million.
- Non-GAAP net loss was $2.7 million, or $0.03 per share, compared with $13.2 million, or $0.27 per share, in the 3rd quarter of 2025; GAAP net loss was $11.5 million, or $0.13 per share.
- Heartflow ended the quarter with $253 million in cash, cash equivalents, and investments.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Nick Laudico, Vice President of Investor Relations.
Please go ahead. Good afternoon, everyone, and welcome to the Heartflow third quarter 2026 earnings conference call.
Joining me today are John Farquhar, Heartflow's President and Chief Executive Officer, and Vikram Verghese, our Chief Financial Officer. Today, we will walk you through our Q3 performance, share updates on our commercial momentum and clinical programs, and provide financial guidance. A live Q&A session will follow. The earnings release accompanying today's discussion is available on our investor relations website at ir.heartflow.com. During this call, we will refer to certain non-GAAP financial measures. Reconciliations to the most comparable GAAP figures can be found in today's earnings release. I'd like to remind everyone that certain statements made on this call are forward-looking within the meaning of federal securities laws. These statements are based on management's current expectations and beliefs, involve risks and uncertainties, and actual results may differ materially.
Please note that both this live call and a digital replay will be available shortly after the call concludes. With that, I'll now turn the call over to John Farquhar, our CEO.
Thank you for joining us. Q3 was another outstanding quarter for Heartflow. The momentum we built in the first half accelerated into the second, and I couldn't be more pleased with the performance of the business. We continue to make excellent progress on our mission to advance the Heartflow AI platform as the new standard of care for detecting, diagnosing, managing, and treating coronary artery disease. For the third consecutive quarter, our year-over-year revenue growth accelerated, and we finished ahead of our expectations, a credit to our expanding category leadership, the power of our platform, and a strong CCTA market. I again want to thank the Heartflow team for their outstanding execution and dedication to the patients we serve. Our results are a direct reflection of their work.
In the third quarter, total revenue was $72.9 million, up 57% year-over-year, with U.S. revenue up 60%, our fastest U.S. growth in 11 quarters. Four factors drove the quarter. First, Plaque Analysis adoption continued to accelerate. Second, FFRct utilization remained durable across our existing accounts. Third, new account additions were strong again, and the 340 accounts we added in 2025, which was our largest cohort ever, continued to ramp as planned. Finally, the CCTA market continued to grow rapidly, driven by guidelines, reimbursement, and physician demand. At only 11% penetrated of the non-invasive testing market, CCTA has a long runway ahead. The strength of our performance through the first nine months gives us the confidence to raise our full-year outlook again. We are raising our total revenue outlook to $262 million-$264 million, up 49%-50% year-over-year.
We are raising our Plaque Analysis revenue outlook to $36 million-$37 million, and we now expect approximately 1,300 plaque-activated accounts by year-end. Moving down the P&L, we are raising our non-GAAP gross margin guidance to approximately 82.5%, driven by a greater mix of high-margin Plaque Analysis revenue, volume leverage, and ongoing AI efficiencies. The midpoint of our revenue guidance implies non-GAAP gross profit growth of nearly 60% year-over-year, outpacing our revenue growth. We remain confident in our midterm non-GAAP gross margin target of 85%. Our accelerating top-line growth, expanding gross margins, and disciplined operational investment gives us even greater confidence in achieving our midterm profitability goals. Let me share a few highlights from the quarter, starting with commercial adoption. First, our category-leading installed base continues to expand. We had another strong quarter of new account additions, and every new account expands the base from which we drive broader platform utilization.
Given the strength of our funnel, we now expect new account activations in 2026 to exceed the 340 that we added in 2025. Turning to Plaque Analysis, we delivered another outstanding quarter, with continued momentum across account activations, physician utilization, and payer coverage. Account activations were strong, driven by the leverage of our installed base and high demand for our market-leading Plaque Analysis. Physician utilization is also expanding. Physicians are moving beyond FFRct patients and using Plaque Analysis across a wider share of their CCTAs, which is exactly what we expected. Broader Plaque Analysis utilization is an important durable tailwind for the business. Payer coverage continues to increase, with Plaque Analysis now covered for approximately 82% of U.S. lives. Shifting now to FFRct, I am pleased to share that physician demand and utilization remain strong and durable.
Our 2025 cohort continues to deliver, and utilization from our 2026 cohort is strong through the first nine months of the year. FFRct remains a powerful driver of our business. It is backed by a wealth of clinical data, most notably four randomized controlled trials, uniquely differentiated with lesion-specific precision, and prospectively validated against the invasive gold standard of FFR. Our clinical evidence and product differentiation give me high confidence FFRct's strong performance will continue. Next, we also made good progress on further strengthening our platform with the continued rollout of PCI Navigator, our unique solution to enable pre-procedural CT-guided PCI planning. Navigator is the first and only PCI planning tool built on prospectively validated FFRct and Plaque Analysis, giving interventional cardiologists the anatomy, plaque, and physiology they need to plan each procedure before entering the cath lab.
In late October at TCT, in conjunction with the P4 RCT readout, we announced a collaboration with Boston Scientific to advance CT-guided PCI planning. We believe this is further validation of the CT-first plus Heartflow pathway and will accelerate awareness of Navigator's clinical benefits with interventional cardiologists. I am highly confident Navigator will embed Heartflow even further into our accounts and help establish interventional cardiologists as powerful advocates for a CT plus Heartflow pathway. Our strong performance in Plaque and FFRCT also reflects the unique power of the Heartflow AI platform. Caring for a patient with CAD requires coordination, from the referring physician to the CT reader to the interventionalist. Our physicians coordinate across the care pathway, and they demand the same from their technology. Disjointed point solutions won't work at scale. Our AI platform does. It's a complete solution to detect, diagnose, manage, and treat patients.
On the front of our pathway, our Roadmap Analysis improves reading efficiency, reduces variability, and is delivered automatically into our customer's workstation on every patient that receives a CCTA scan. Because it's available on all scans, independent of stenosis or disease level, it serves as the launch pad for our reimbursed Plaque and FFRCT analyses, which in turn provide distinct complementary insights to diagnose and manage disease. PCI Navigator now extends our AI precision into the cath lab, helping interventional cardiologists complete the care pathway with precision. From first scan to treatment planning, the Heartflow AI platform provides a complete solution for CAD. Alongside our strong commercial momentum, our clinical evidence base continues to grow, with important new data strengthening the case for Heartflow as the new standard of care. Let me highlight four recent readouts.
First, at AHA in November, we presented our one-year outcomes from a propensity-matched analysis of our prospective DECIDE registry of more than 6,000 patients. Patients managed with Heartflow Plaque Analysis had 34% fewer major CVD events and half the rate of heart attack at one year compared to those managed with CCTA alone. 50% of patients reached target LDL-C by 90 days compared to just 35% with CCTA alone, and these improvements were sustained through one year. The one-year findings demonstrate that Heartflow Plaque Analysis provides clinicians with the objective outcomes data needed to optimize preventative care earlier and with greater precision, while significantly reducing major CVD events and heart attacks compared to CCTA alone. The DECIDE one-year outcomes make Heartflow Plaque Analysis the first and the only plaque tool with prospective outcomes data, another important differentiator and tailwind for plaque adoption.
Also at TCT, the P4 study, the only randomized trial of CT-guided PCI planning, was presented, with the results published simultaneously in the New England Journal of Medicine. P4 compared CT-guided PCI planning enabled by Heartflow with the gold standard IVUS-guided planning. P4 met its primary endpoint. CT-guided PCI matched gold standard IVUS on one-year target vessel failure rate. CT guidance also cut median procedure time by 27%, used about 12% less contrast, and more than doubled the use of advanced calcium modification tools like IVL. Put simply, P4 showed CT-guided PCI planning can improve the efficiency and precision of PCI with no compromise on outcomes. We also released our NAVIGATE-PCI registry data at TCT, which measured in real-world U.S. settings how PCI procedures changed when PCI Navigator was provided as compared to standard planning. CT-guided planning with Navigator changed the procedural plan in approximately 70% of patients.
Importantly, anatomy, plaque, and physiology each drove changes in the plan, and Navigator is the only tool that brings all three together. Together, both of these studies give PCI Navigator an unmatched clinical evidence base. We believe these results further establish the CT-first pathway and Heartflow as a platform as an emerging standard of care, while setting the stage for Navigator's broader rollout in 2027. Lastly, our FFRCT evidence base got even stronger in the third quarter. FUSION, an independent Dutch government-funded randomized controlled trial, read out at ESC in August and became the fourth randomized controlled trial supporting the use of FFRCT. Turning to our future, as we've discussed previously, expanding into the high-risk asymptomatic market represents our third wave of growth, a roughly $6 billion opportunity, bringing our total U.S. TAM to approximately $11 billion.
We've designed three randomized controlled trials to generate the evidence needed to expand the use of Plaque Analysis across three high-risk asymptomatic populations. REFINE-CAC, our trial for patients with coronary artery calcium, a $3 billion opportunity, and REWRITE-CAD, our trial for patients with prior MI or PCI, a $1 billion opportunity, are both expected to begin enrolling in the fourth quarter of 2026. Evolve Plaque, our serial plaque study with Amgen in patients with known plaque, is a $2 billion opportunity, and it's expected to begin enrolling in the first quarter of 2027. The clinical goal is simple: identify and measure coronary disease earlier and give physicians the information they need to intervene before a cardiac event. High-risk asymptomatic patients have substantial clinical needs and account for significant healthcare costs. We believe positive results on the trial's primary endpoint can support expanded coverage under the existing Plaque Analysis LCD.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
